摘要
当前胶质瘤的病理分级由于胶质瘤频发异质性显得相形见绌。蛋白质组学的发展为高通量筛选与胶质瘤发病相关的蛋白质类生物标志物提供了强有力的工具，联合多种蛋白质生物标志物进行胶质瘤的筛检将有望提高肿瘤筛检的特异性与敏感性。蛋白质组学技术为从分子水平界定胶质瘤分级，客观评价不同类型胶质瘤的演进特征，准确判断预后，以及进行新药研发提供了可能。
Current pathological diagnosis of glioma grades is difficult because of the existence of tumor heterogeneity. The development of proteomics can be a good tool for high-flux screening protein marks related to glioma. The combination of multiple proteins may enhance detecting specificity and sensitivity for glioma diagnosis. And the proteomics may offer chances for glioma grading in molecular level, objectively evaluating biological characteristics of different tumor types ,judging prognosis,and studying new therapy drugs.
出处
《国际肿瘤学杂志》
CAS
2009年第7期517-520,共4页
Journal of International Oncology
基金
基金项目：国家自然科学基金资助项目（30670621）
